Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bepotastine besilate + fluticasone propionate is a combination of two pharmaceutical agents used for the treatment of allergic conditions, particularly allergic rhinitis. Bepotastine besilate is a second-generation non-sedative antihistamine that acts as a Histamine H1 receptor (H1R) antagonist, blocking the effects of histamine and thereby reducing symptoms such as itching and sneezing[4][5]. Fluticasone propionate is a synthetic corticosteroid that reduces inflammation by inhibiting multiple types of inflammatory cells and decreasing the production of mediators involved in allergic responses[3][6]. While both drugs are individually approved for use in various forms (ophthalmic solution for bepotastine; nasal spray or inhaler for fluticasone), there is no widely marketed fixed-dose combination product containing both agents together. However, clinical trials have evaluated their combined use in treating seasonal allergic rhinitis[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bepotastine besilate + fluticasone propionate.